Swedbank AB Purchases 6,814 Shares of Humana Inc. (NYSE:HUM)

Swedbank AB lifted its position in shares of Humana Inc. (NYSE:HUM) by 6.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 112,790 shares of the insurance provider’s stock after purchasing an additional 6,814 shares during the quarter. Swedbank AB owned about 0.09% of Humana worth $28,616,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. International Assets Investment Management LLC grew its stake in shares of Humana by 261,025.1% in the 3rd quarter. International Assets Investment Management LLC now owns 738,984 shares of the insurance provider’s stock worth $2,340,660,000 after buying an additional 738,701 shares during the last quarter. FMR LLC grew its stake in shares of Humana by 23.4% in the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock worth $1,073,387,000 after acquiring an additional 643,291 shares during the last quarter. Thrivent Financial for Lutherans increased its holdings in shares of Humana by 55.6% during the third quarter. Thrivent Financial for Lutherans now owns 600,317 shares of the insurance provider’s stock valued at $190,145,000 after acquiring an additional 214,535 shares in the last quarter. Pzena Investment Management LLC raised its position in shares of Humana by 8.1% in the 3rd quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock worth $793,830,000 after purchasing an additional 187,903 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC bought a new position in Humana in the 3rd quarter worth about $50,102,000. Institutional investors own 92.38% of the company’s stock.

Insider Activity

In related news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.32% of the company’s stock.

Humana Price Performance

Shares of Humana stock opened at $296.88 on Friday. The firm has a market cap of $35.75 billion, a PE ratio of 26.30, a PEG ratio of 2.15 and a beta of 0.55. The stock has a 50 day moving average of $275.44 and a 200 day moving average of $303.07. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.68. The firm had revenue of $29.30 billion for the quarter, compared to analysts’ expectations of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. On average, research analysts expect that Humana Inc. will post 16.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on HUM. Sanford C. Bernstein upgraded shares of Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price objective for the company in a research note on Tuesday, October 8th. TD Cowen upped their price objective on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Deutsche Bank Aktiengesellschaft cut their target price on shares of Humana from $349.00 to $250.00 and set a “hold” rating for the company in a research report on Thursday, October 3rd. Morgan Stanley upped their price objective on Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 17th. Finally, Bank of America raised Humana from an “underperform” rating to a “neutral” rating and raised their target price for the stock from $247.00 to $308.00 in a research report on Wednesday, November 6th. Nineteen research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Humana has an average rating of “Hold” and a consensus price target of $297.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.